Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | GBA1 | P04062 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 2/20 | 0.33 |
| ▸ | THRA | P10827 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4551240 | 0.83 | GBA1 (0.41) | CYP1A2GBA1TP53 | |
| SCHEMBL2783717 | 0.83 | GBA1 (0.41) | CYP1A2GBA1TP53 | |
| SCHEMBL3146990 | 0.77 | GBA1 (0.41) | GBA1TP53 | |
| SCHEMBL27823762 | 0.77 | PIK3CD (0.38) | MAPTGBA1TP53THRB | |
| SCHEMBL27823764 | 0.77 | PIK3CD (0.38) | MAPTGBA1TP53THRB | |
| SCHEMBL10337392 | 0.73 | MAN2B1 (0.38) | CYP1A2GBA1 | |
| SCHEMBL7611955 | 0.73 | PIK3CD (0.34) | GBA1TP53 | |
| SCHEMBL4416368 | 0.71 | GBA1 (0.41) | CYP1A2MAPTGBA1TP53THRB | |
| SCHEMBL13261436 | 0.71 | GBA1 (0.41) | CYP1A2MAPTGBA1TP53THRB | |
| SCHEMBL13261425 | 0.71 | GBA1 (0.41) | CYP1A2MAPTGBA1TP53THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0681474-B1 | PHARMACEUTICAL COMPOSITION CONTAINING 5-MORPHOLINOMETHYL-3-(4-CHLOROBENZYLIDENEAMINE)-2-OXAZOLIDINONE AND ITS USE FOR THE TREATMENT OF CNS DISORDERS | INST FARMACEUTYCZNY (PL) | 1999-04-07 | — | — | EP | disclosed |
| US-5643907-A | Pharmaceutical composition containing 5-morpholinomethyl-3-(4-chlorobenzylideneamine)-2-oxazolidinone and its use for the treatment of CNS disorders | INSTYTUT FARMACEUTIYCZNY (PL) | 1997-07-01 | — | — | US | disclosed |
| EP-0681474-A1 | PHARMACEUTICAL COMPOSITION CONTAINING 5-MORPHOLINOMETHYL-3-(4-CHLOROBENZYLIDENEAMINE)-2-OXAZOLIDINONE AND ITS USE FOR THE TREATMENT OF CNS DISORDERS | INSTYTUT FARMACEUTYCZNY (PL) | 1995-11-15 | — | — | EP | disclosed |
| WO-1994016705-A2 | PHARMACEUTICAL COMPOSITION CONTAINING 5-MORPHOLINOMETHYL-3-(4-CHLOROBENZYLIDENEAMINE)-2-OXAZOLIDINONE AND ITS USE FOR THE TREATMENT OF CNS DISORDERS | INSTYTUT FARMACEUTYCZNY (PL) | 1994-08-04 | — | — | WO | disclosed |